Molecular structure of Ixazomib, CAS Number: 1072833-77-2
Ixazomib (CAS 1072833-77-2)
Alternate Names:
MLN2238
CAS Number:
1072833-77-2
Molecular Weight:
361.03
Molecular Formula:
C14H19BCl2N2O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
As a proteasome inhibitor, Ixazomib works by interfering with the proteasome′s function, a complex in cells responsible for degrading unneeded or damaged proteins. By inhibiting the proteasome, Ixazomib disrupts various cellular processes, particularly those involving protein degradation. The mechanism of action of Ixazomib primarily involves the selective and reversible inhibition of the 20S proteasome, a core component of the larger 26S proteasome complex. This inhibition leads to the accumulation of damaged or misfolded proteins within the cells.
Ixazomib (CAS 1072833-77-2) References
- The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. | Richardson, PG., et al. 2015. Future Oncol. 11: 1153-68. PMID: 25832873
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. | Moreau, P., et al. 2016. N Engl J Med. 374: 1621-34. PMID: 27119237
- The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. | Brayer, J. and Baz, R. 2017. Ther Adv Hematol. 8: 209-220. PMID: 28694935
- New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. | Richardson, PG., et al. 2017. J Blood Med. 8: 107-121. PMID: 28860887
- The proteasome and proteasome inhibitors in multiple myeloma. | Gandolfi, S., et al. 2017. Cancer Metastasis Rev. 36: 561-584. PMID: 29196868
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. | Chim, CS., et al. 2018. Leukemia. 32: 252-262. PMID: 29257139
- Ixazomib-induced cutaneous necrotizing vasculitis. | Alloo, A., et al. 2018. Support Care Cancer. 26: 2247-2250. PMID: 29392482
- Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal. | Armoiry, X., et al. 2018. Pharmacoeconomics. 36: 1073-1081. PMID: 29582405
- Ixazomib and lenalidomide maintenance therapy in multiple myeloma. | Parrondo, RD., et al. 2021. Ann Hematol. 100: 851-853. PMID: 33161454
- Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice. | Micheletto, MLJ., et al. 2021. Int J Exp Pathol. 102: 11-21. PMID: 33296126
- Ixazomib inhibits myeloma cell proliferation by targeting UBE2K. | Wang, Q., et al. 2021. Biochem Biophys Res Commun. 549: 1-7. PMID: 33647537
- Ixazomib Induces Apoptosis and Suppresses Proliferation in Esophageal Squamous Cell Carcinoma through Activation of the c-Myc/NOXA Pathway. | Wang, T., et al. 2022. J Pharmacol Exp Ther. 380: 15-25. PMID: 34740946
- Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. | Auner, HW., et al. 2022. Blood Cancer J. 12: 52. PMID: 35365598
- Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. | Slade, M., et al. 2022. Leukemia. 36: 2917-2921. PMID: 36114265
Inhibitor of:
20S Proteasome α1, 20S Proteasome α2, 20S Proteasome α5, 20S Proteasome α7, 20S Proteasome α8, 20S Proteasome β1, 20S Proteasome β2, 20S Proteasome β5, 20S Proteasome β7, 26S Proteasome, 26S Proteasome α, 26S Proteasome p42C, 26S Proteasome p48A, 26S Proteasome p50, 26S Proteasome p54, 26S Proteasome p58, 4933422H20Rik, ABCF2, AOS-1, ASB-2, AV320801, C6orf113, CARD11, CCP5, Cdc23, CRBN, CSN7b, Dcun1D1, Dda1, DDI2, Derlin-1, DET1, E2ig5, EG382106, EG382156, EG668359, FBXO48, Fbxw12, FBXW23, Gigaxonin, Glomulin, Gm514, Gm757, HECTD4, Herc1, Ig κ light chain, Ikaros, IQUB, Josephin-2, Josephin-3, KBTBD11, KBTBD4, KCMF1, KIAA1984, KLHDC1, KLHDC4, KLHL33, LNX1, LONRF1, Makorin-2, MECL-1, MIB1, NEURL4, NHLRC3, NOB1P, Nup62-il4i1, Olr113, Olr1217, Olr168, Olr170, Olr517, Olr532, Olr560, Olr649, Olr653, Olr696, Olr704, Olr724, Olr736, Olr750, PA, PARC, PIH1D2, PJA1, Plasma Cell, PLIC-1, PRAME_Prame, Proteassemblin, PSMB11, PSMB4, PSMB6, PSMC1, PSMC2, PSMC3, PSMC4, PSMC6, PSMD11, PSMD12, PSMD13, PSMD5, PSMD7, PSMD8, PSME proteasome activator subunits (PA28), Rad23, RFPL4A, RMND5A, RNF103, RNF130, RNF148, RNF152, RNF166, RNF180, RNF182, RNF187, RNF219, RNF24, Rpb3, Rpn11, SEL-10, SHARPIN (SHANK associated RH domain interactor), SHFM3, Slimb, SUG1, THOC1, TRIM11, TRIM23, TRIM31, TRIM34B, TRIM40, TRIM45, TRIP15, Ub, UBAP2, UBCE7IP4, UBE2CBP, UBE3B, UBQLN3, Ubr2, UBXD7, USP21, USP29, V1RH5, Vta1, WDR20a, ZFAND1, ZFP91, ZGPAT, ZNF114, and ZNF121.Activator of:
20S Proteasome α3, 20S Proteasome α6, 20S Proteasome β3, A1Up, ASB-7, CRLF3, ECM29, FBXO30, FBXO35, Fbxw13, KLF16, Neuralized-2, PI31, PLIC-2, POH1, PSMD2, PSMD8, Rad23A, RNF113B, TRIP12, UBAP1, UBE1L2, UBE2J2, and UCH-L3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ixazomib, 10 mg | sc-489103 | 10 mg | $311.00 | |||
Ixazomib, 50 mg | sc-489103A | 50 mg | $719.00 |